GNRH1 and osteoporosis: Given the mechanism of action for elagolix, the study did not include women with a history of nonresponse to GnRH agonists or antagonists, depot medroxyprogesterone acetate, or aromatase inhibitors.26 Patients with a history of osteoporosis or other metabolic bone disease were also excluded.